Traws Pharma Inc
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marbox… Read more
Traws Pharma Inc (TRAW) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.883x
Based on the latest financial reports, Traws Pharma Inc (TRAW) has a cash flow conversion efficiency ratio of -0.883x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.01 Million) by net assets ($4.54 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Traws Pharma Inc - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Traws Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Traws Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Traws Pharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MiMedia Holdings Inc.
V:MIM
|
0.366x |
|
Daura Gold Corp.
V:DGC
|
-0.601x |
|
PTL Enterprises Limited
NSE:PTL
|
0.025x |
|
Valor Resources Limited
PINK:VOYRF
|
-0.024x |
|
Innofactor Oyj
HE:IFA1V
|
0.044x |
|
CAFOM S.A. INH. EO 510
F:CAA
|
N/A |
|
CN SINGYES
F:KG0A
|
-0.022x |
|
Ha Noi South Housing and Urban Development Corp
VN:NHA
|
N/A |
Annual Cash Flow Conversion Efficiency for Traws Pharma Inc (2011–2024)
The table below shows the annual cash flow conversion efficiency of Traws Pharma Inc from 2011 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-31.63 Million | $-29.79 Million | 0.942x | +156.06% |
| 2023-12-31 | $10.67 Million | $-17.93 Million | -1.680x | -191.93% |
| 2022-12-31 | $28.31 Million | $-16.29 Million | -0.576x | -36.22% |
| 2021-12-31 | $46.12 Million | $-19.49 Million | -0.423x | +88.69% |
| 2020-12-31 | $6.17 Million | $-23.07 Million | -3.737x | -107.62% |
| 2019-12-31 | $11.57 Million | $-20.83 Million | -1.800x | +57.28% |
| 2018-12-31 | $5.39 Million | $-22.70 Million | -4.213x | -292.10% |
| 2017-12-31 | $-10.86 Million | $-23.82 Million | 2.193x | +171.11% |
| 2016-12-31 | $5.13 Million | $-15.81 Million | -3.084x | -6.77% |
| 2015-12-31 | $10.84 Million | $-31.31 Million | -2.889x | -18.37% |
| 2014-12-31 | $23.62 Million | $-57.65 Million | -2.440x | -221.63% |
| 2013-12-31 | $80.90 Million | $-61.38 Million | -0.759x | -7255.60% |
| 2012-12-31 | $-158.31 Million | $1.63 Million | -0.010x | -110.08% |
| 2011-12-31 | $-138.42 Million | $-14.17 Million | 0.102x | -- |